OBJECTIVE The objective of this study was to assess and compare the features of the Bemfola, Gonal-f and Puregon injection pens. METHODS Females who intended to undergo hormonal treatment received the three different pens in a randomized, consecutive sequence. For each of the pens, the potential patients completed an Injection Pen Assessment Questionnaire, as well as a questionnaire comparing the handling, convenience and preference among the three pens. RESULTS The mean score on the visual analogue scale (VAS) for the Bemfola pen (BP) was 77.8 ± 14.0; for the Puregon pen (PP), 72.1 ± 12.4; and for the Gonal-f pen (GP), 68.6 ± 16.4. The BP was superior to both competitor devices in pen size, inconspicuousness, ease of use and dose changing; no significant differences to both competitor pens were observed in the way the pen looks, the way the pen feels and the ease of injection of the volume. The 'overall' assessment was significantly better for the BP when compared to the GP (p = 0.0019), while no significant difference was observed between the BP and the PP. CONCLUSIONS This study demonstrated significantly higher ratings for pen size, inconspicuousness, ease of use and dose adjustment for the BP compared to other marketed pens.
Bemfola, a biosimilar r-hFSH, is delivered in a novel, innovative injector pen system 33 (reddot design award 2011). The bemfola pen is a single-use, disposable pen 34 available in 5 different dose strengths (i.e., 75IU, 150IU, 225IU, 300IU and 450IU). 35
The bemfola pen allow a fine-tuned dosing adjustment in 12.5IU and 25IU 36 increments. Other characteristics of the single-use pen are volume and injection-37 control mechanisms by visual aids such as coloured bars indicating the injection 38 volume. The clearly legible selected dose (as well as a click signal after successful 39 copmletion of the injection) avoid dosing errors, which in turn may improve therapy 40 compliance. If patients need a lower dose than the maximum ejection volume, an in-41 built lock prevents re-use of the pen device in order to reduce redosing for patient 42 safety. The remaining dose is discarded. 43
Non-compliance to hormonal treatment regimens represents a critical obstacle to 44 reaching therapeutic goals [1] [2] [3] [4] . The use of pens by patients is often limited by factors 45 such as fear of injection, but correct use of the pen can be also related to the device 46 itself. Accordingly, easy-to-use devices may positively influence patient compliance.
The convenient and simple handling of a pen would be expected to increase 48 adherence to the prescribed treatment regimen and therefore lead to a higher 49 success rate of hormonal treatment. 50
The objective of this study was to assess and compare the features of the bemfola vs. (01 to 36) indicated for each user a randomly assigned sequence. Users received the 76 3 pens one after the other in a randomly indicated sequence. 77
Testing Procedure: Subjects were informed about this survey by the treating 78 physician or study nurse during regular visits at the fertility centre while discussing 79 an anticipated hormonal fertility treatment. Upon receiving the subject's consent to 80 participate, the treating physician or the study nurse conducted the survey. Each 81 subject was instructed by the treating physician or the study nurse and tested 82 consecutively all 3 pens (cross-over design with random sequence). The treating 83 physician or the nurse explained how to use the first of the 3 pens (BP, GP or PP); 84 subjects were instructed to start with an intended administration of 225IU a day 85 followed by a dose increase to 300IU. The instruction included also the use of the 86 closing cap as well as disposing of the needle after injection. The subject then 87 independently completed the entire handling procedure (without help or support 88 from the study nurse or the treating physician) with the first pen. The pen contents 89 were injected into a demonstration cushion. Afterwards the subject's responses 90 were recorded in the first questionnaire (Q1). This procedure was repeated exactly 91 the same way for the second and for the third pen, then completing the second 92 questionnaire (Q2) and the third questionnaire (Q3) respectively. After the evaluation of all 3 pens was finished, subjects were asked to complete a concluding 94 questionnaire (QEnd), comparing the handling, convenience and preference of all 95 the 3 pens. 96
Assessments: Information on baseline characteristics (i.e., age and confirmation that 97 potential patients had never previously used a pen delivery system for IVF 98 treatment) was collected from each subject. Questionnaire structure for each pen 99 (Q1, Q2, Q3) addressed appearance and perception (size, handling during injection, 100 overall opinion) as well as comparative preferences and convenience at the end 101 (QEnd). The following scores were used: 1=best pen, 2= second best pen, 3=last 102 choice). 103
Statistical methods: Complete Case Record Forms (CRFs) consisting of Q1, Q2, Q3, 104 and QEnd were collected; single data entry was made on an Oracle database and 105 descriptive statistics were performed. The pre-defined objective for reported 106 features of pens defined a difference of 20±50 on the VAS score (0 to 100) as 107 significant when BP was compared with GP and PP, respectively. A sample size of 52 108 had an 80% power to detect a difference in means of 20 (e.g., a first-condition mean 109
[µ 1 ] of 50 and a second-condition mean [µ 2 ] of 30) assuming a standard deviation of 110 differences of 50 and using a paired t-test with a 0.050 2-sided significance level. In 111 order to compensate for potential drop-outs and invalid completion of CRFs, a 112 population of 60 users was considered to be sufficient. All users who completed 113 questionnaires for all 3 pens and the final assessments (Q1, Q2, Q3 and QEnd) were 114 included in the analysis. User-reported outcomes (VAS Scores) and ranking scores 115 were assessed using descriptive statistics. The T-test for quantitative data was used to analyse all VAS scores of all items for the 3 pens, while the preference ranking 117 score was assessed with a Wilcoxon signed-rank test for categorical data. 118
Results 120
121
The highest numerical mean VAS scores were observed for the bemfola pen in 10 122 out of 11 items (table 1 and figure 1) . As a consequence, the overall mean score of 123 the bemfola pen was the highest with 77.8±14.0 followed by the Puregon pen 124 (72.1±12.4) and the Gonal-f pen (68.6±16.4). 125
Statistical analysis revealed significantly higher VAS scores for the bemfola pen in 8 126 out of 11 items when compared to the Gonal-f pen, and in 4 out of 11 items when 127 compared to the Puregon pen. The bemfola pen was superior to both competitor 128 devices in pen size, inconspicuousness, ease of use, and dose changing; no 129 significant differences to either competitor pen were observed in the way the pen 130 looks, the way the pen feels, and the easiness to inject the pen volume (table 1). The 131 "Overall" assessment was significantly better for the bemfola pen when compared to 132
the Gonal-f pen (p=0.0019), while no significant difference was observed between 133 the bemfola and Puregon pen. 134
The bemfola pen showed the highest proportion of "best" choice in all 8 preference 135 and convenience items (table 2 and figure 2). The total mean proportion of the "best" 136 ranking for the bemfola pen was 62% and markedly higher compared to the mean 137 proportion for the "best" ranking for the Puregon pen (26%) and the Gonal-f pen 138 (12%). The proportion of "last" ranking was highest in 5 items (size, appearance, 139 holding, inconspicuousness, and injection performance) for the Gonal-f pen and in 2 140 items for the Puregon pen (learning of use and injection preparation) and similar for both pens, the Gonal-f pen and the Puregon pen, with regards to injection handling 142 (handling after the injection). Outcomes on features and preferences of the 3 pens were consistent for the 167 majority of assessments. The bemfola pen showed higher VAS scores and clearly 168 better rankings for the pen size, the learning and facility in using the pen compared 169
to both Gonal-f and Puregon pens. The "inconspicuousness" of the bemfola pen was a 170 significantly better feature compared to both competitors and showed a 171 significantly higher preference when matched to the Gonal-f pen, while the 172 preference compared to the Puregon pen showed a positive trend in favour of the 173 bemfola ® pen (p=0.0615). 174
The VAS scores of the bemfola pen on the appearance ("how the pen looks") and feel 175 ("how the pen feels") were similar when related to both challengers, while the 176 preference of the bemfola pen on appearance ("how the pen looks") and handling 177 ("holding in your hands") was significantly higher when compared to the Gonal-f pen. There were also features such as injecting the volume or the preference on 179 performing the injection which were comparable for all three pens, while the 180 preference for handling after the injection was rated significantly higher for the 181 bemfola pen compared to both the Gonal-f and Puregon pens. 182
The results showed also clearly that the bemfola pen was superior to the Gonal-f pen 183 with regards to the features on priming and overall use of the pen as well as the 184 setting and changing the doses. This is reflected by the significantly higher 185 preference for preparing the injection, while the ratings of these features were 186 similar between both bemfola and Puregon pens. 187
In conclusion, the results of this study demonstrated the benefits of the bemfola pen, 188 as well as the potential patients' preference for the bemfola pen compared to 189 available alternatives. These differences were considerable when compared to the 190 Puregon pen and even more marked regarding the Gonal-f pen based on the 191 potential patients' assessments. These findings suggest that the ease, look and 192 handling of the bemfola pen may potentially translate to increased patient 193 preference and compliance which requires additional study. Size of the pen
The way the pen look
The way the pen feels The size of the pen < 0.0001 0.0004
The way the pen look like 0.0183 n.s.
To hold the pen in your hands 0.0010 n.s.
The inconspicuousness of the pen < 0.0001 n.s.
For learning on how to use the pen < 0.0001 < 0.0001
For preparing the injection < 0.0001 < 0.0001
For performing the injection n.s. n.s.
For handling after the injection < 0.0001 < 0.0001 246 
